DOI QR코드

DOI QR Code

Breast Cancer Recurrence According to Molecular Subtype

  • Shim, Hee Jin (Department of Radiology, The Catholic University of Korea, Seoul St. Mary's Hospital) ;
  • Kim, Sung Hun (Department of Radiology, The Catholic University of Korea, Seoul St. Mary's Hospital) ;
  • Kang, Bong Joo (Department of Radiology, The Catholic University of Korea, Seoul St. Mary's Hospital) ;
  • Choi, Byung Gil (Department of Radiology, The Catholic University of Korea, Seoul St. Mary's Hospital) ;
  • Kim, Hyeon Sook (Department of Radiology, The Catholic University of Korea, St. Paul Hospital) ;
  • Cha, Eun Suk (Department of Radiology, Mokdong Hospital, Ewha Woman's University, School of Medicine) ;
  • Song, Byung Joo (Department of Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital)
  • Published : 2014.07.30

Abstract

Background: To evaluate the location of tumor relapse and imaging modality for detection according to the breast cancer subtype: luminal A, luminal B, HER2 positive luminal B, nonluminal HER2 positive, and triple negative. Materials and Methods: A total of 1244 patients with breast cancer with known estrogen receptor (ER), progesterone receptor (PR), Ki-67 and human epidermal growth factor receptor 2 (HER2), who underwent breast surgery from 2009 to 2012 were analyzed. Patients were classified into the following categories: luminal A (n=458), luminal B (n=241), HER2 positive luminal B (n=227), nonluminal HER2 positive (n=145) and triple negative (n=173). A total of 105 cases of relapse were detected in 102 patients: locoregional recurrence (n=46), recurrence in the contralateral breast (n=28) and distant metastasis (n=31). Comparison of proportions was used to determine the difference between subtypes. Results: Relapse rates by subtypes are as follows: luminal A 23 of 458 (5.02%), luminal B 19 of 241(7.88%), HER2 positive luminal B 15 of 227 (6.61%), nonluminal HER2 postive 19 of 145 (13.10%) and triple negative 29 of 173(16.76%). Luminal A tumors had the lowest rate of recurrence and had significantly lower recurrence rate in comparison with nonluminal HER2 postive (p=0.0017) and triple negative subtypes (p<0.0001). Compared with all other subtypes except nonluminal HER2 positive, triple negative tumors had the highest rate of tumor recurrence (p<0.01). Triple negatives were most likely to develop contralateral recurrence against all subtypes (p<0.05). Detection rate of locoregional and contralateral tumor recurrence were 28.3% on mammography (n=17/60). Conclusions: Luminal A tumors are associated with a low risk of recurrence while triple negative lesions have a high risk. In case of triple negative tumors, the contralateral breast has much more recurrence as compared with all other subtype. In terms of detection rates, breast USG was the best modality for detecting tumor recurrence, compared with other modalities (p<0.05). Subtyping of breast tumors using a molecular gene expression panel can identify patients who have increased risk of recurrence and allow prediction of locations of tumor recurrence for each subtype.

Keywords

References

  1. Bessonova L, Taylor TH, Mehta RS, et al (2011). Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev, 20, 389-96. https://doi.org/10.1158/1055-9965.EPI-10-1016
  2. Garcia Fernandez A, Gimenez N, Fraile M, et al (2012). Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010. Breast, 21, 366-73. https://doi.org/10.1016/j.breast.2012.03.004
  3. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
  4. Gordon PB, Goldenberg SL (1995). Malignant breast masses detected only by ultrasound. A retrospective review. Cancer, 76, 626-30. https://doi.org/10.1002/1097-0142(19950815)76:4<626::AID-CNCR2820760413>3.0.CO;2-Z
  5. Haffty BG, Yang Q, Reiss M, et al (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24, 5652-7. https://doi.org/10.1200/JCO.2006.06.5664
  6. Houssami N, Ciatto S, Martinelli F, et al (2009). Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol, 20, 1505-10. https://doi.org/10.1093/annonc/mdp037
  7. Kadivar M, Mafi N, Joulaee A, et al (2012). Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011. Asian Pac J Cancer Prev, 13, 1881-6. https://doi.org/10.7314/APJCP.2012.13.5.1881
  8. Kim HJ, Kwak JY, Choi JW, et al (2010). Impact of US surveillance on detection of clinically occult locoregional recurrence after mastectomy for breast cancer. Ann Surg Oncol, 17, 2670-6. https://doi.org/10.1245/s10434-010-1087-z
  9. Lowery AJ, Kell MR, Glynn RW, et al (2012). Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat, 133, 831-41. https://doi.org/10.1007/s10549-011-1891-6
  10. Malone KE, Begg CB, Haile RW, et al (2010). Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol, 28, 2404-10. https://doi.org/10.1200/JCO.2009.24.2495
  11. Najafi B, Anvari S, Roshan ZA (2013). Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2010 in Iran. Asian Pac J Cancer Prev, 14, 5811-6. https://doi.org/10.7314/APJCP.2013.14.10.5811
  12. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
  13. Spitale A, Mazzola P, Soldini D, et al (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol, 20, 628-35. https://doi.org/10.1093/annonc/mdn675
  14. Tun NM, Villani GM, Ong K (2011). Risk of having BRCA mutations in women with triple-negative breast cancer: a systematic review and meta-analysis. J Clin Oncol, 29, 160.
  15. van 't Veer LJ, Dai H, van de Vijver MJ, et al (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6. https://doi.org/10.1038/415530a
  16. Voduc KD, Cheang MC, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684-91. https://doi.org/10.1200/JCO.2009.24.9284

Cited by

  1. Correlation between Ki67 and Histological Grade in Breast Cancer Patients Treated with Preoperative Chemotherapy vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10277
  2. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women vol.151, pp.1, 2015, https://doi.org/10.1007/s10549-015-3390-7
  3. Impact of Age, Tumor Size, Lymph Node Metastasis, Stage, Receptor Status and Menopausal Status on Overall Survival of Breast Cancer Patients in Pakistan vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1019
  4. Contralateral Breast Cancer: a Clinico-pathological Study of Second Primaries in Opposite Breasts after Treatment of Breast Malignancy vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1207
  5. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice vol.163, pp.3, 2017, https://doi.org/10.1007/s10549-017-4206-8
  6. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype vol.24, pp.11, 2017, https://doi.org/10.1245/s10434-017-6021-1
  7. BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis vol.27, pp.4, 2017, https://doi.org/10.1016/j.je.2016.05.002